TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Brii Biosciences Limited ( (HK:2137) ) just unveiled an announcement.
Brii Biosciences Limited announced the publication of its Phase 2 ENSURE study results in Nature Medicine, highlighting the efficacy and safety of elebsiran combined with pegylated interferon alfa (PEG-IFN α) for chronic hepatitis B treatment. The study demonstrated that the combination therapy resulted in higher hepatitis B surface antigen (HBsAg) loss rates compared to PEG-IFN α monotherapy, particularly among patients responsive to the BRII-179 vaccine. These findings suggest a promising role for BRII-179 in enhancing immune response and expanding treatment eligibility, potentially positioning Brii Biosciences as a leader in hepatitis B curative therapies.
The most recent analyst rating on (HK:2137) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Brii Biosciences Limited stock, see the HK:2137 Stock Forecast page.
More about Brii Biosciences Limited
Brii Biosciences Limited is a biotechnology company focused on developing innovative therapies for infectious diseases. The company is engaged in advancing treatments for chronic hepatitis B, utilizing siRNA and therapeutic vaccines to improve patient outcomes.
Average Trading Volume: 6,670,980
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.36B
Learn more about 2137 stock on TipRanks’ Stock Analysis page.